Hypermethylation in Promoter Region of Retinoic Acid Receptor-Beta Gene and Immunohistochemical Findings on Retinoic Acid Receptors in Carcinogenesis of Endometrium

Cancer Lett. 2005 Feb 28;219(1):33-40. doi: 10.1016/j.canlet.2004.06.044.

Abstract

In the present study, we analyzed the immunohistochemical findings for the RA receptor (RAR), retinoic X receptor (RXR) and hypermethylation of promoter-region CpG island methylation of RAR-beta2. Immunohistochemistry indicated that though RXR-alpha and -gamma were present in endometrial hyperplasia and cancer, other retinoid receptors were only weakly detected. The hypermethylation of RAR-beta2 was found in 75.0% of endometrial hyperplasia samples and 92.2% of carcinomas. No normal endometria had methylation. This evidence may point to one of the reasons why endometrial hyperplasia acquires high proliferative capacity without differentiation, and the hypermethylation of RAR-beta2 may occur in the early stage of endometrial carcinogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blotting, Western
  • CpG Islands / genetics
  • DNA Methylation*
  • Endometrial Hyperplasia / genetics*
  • Endometrial Neoplasms / genetics*
  • Estrogen Receptor alpha / biosynthesis
  • Female
  • Humans
  • Immunohistochemistry
  • Promoter Regions, Genetic*
  • Receptors, Progesterone / biosynthesis
  • Receptors, Retinoic Acid / genetics*
  • Retinoid X Receptor alpha / biosynthesis*

Substances

  • Estrogen Receptor alpha
  • Receptors, Progesterone
  • Receptors, Retinoic Acid
  • Retinoid X Receptor alpha
  • retinoic acid receptor beta